Arbutus Biopharma Corp. (ABUS)
4.22
+0.04
(+0.96%)
USD |
NASDAQ |
Oct 09, 16:00
4.21
-0.01
(-0.24%)
After-Hours: 20:00
Arbutus Biopharma Cash from Operations (Quarterly) : -5.952M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.952M |
| March 31, 2026 | -8.11M |
| December 31, 2025 | -4.226M |
| September 30, 2025 | -5.840M |
| June 30, 2025 | -16.26M |
| March 31, 2025 | -13.39M |
| December 31, 2024 | -9.136M |
| September 30, 2024 | -20.76M |
| June 30, 2024 | -14.26M |
| March 31, 2024 | -19.30M |
| December 31, 2023 | -16.23M |
| September 30, 2023 | -21.91M |
| June 30, 2023 | -19.72M |
| March 31, 2023 | -27.30M |
| December 31, 2022 | -15.86M |
| September 30, 2022 | -18.37M |
| June 30, 2022 | -20.29M |
| March 31, 2022 | 20.62M |
| December 31, 2021 | -19.45M |
| September 30, 2021 | -15.33M |
| June 30, 2021 | -14.50M |
| March 31, 2021 | -17.88M |
| December 31, 2020 | -16.03M |
| September 30, 2020 | -13.02M |
| June 30, 2020 | -8.447M |
| Date | Value |
|---|---|
| March 31, 2020 | -15.45M |
| December 31, 2019 | -13.28M |
| September 30, 2019 | -24.01M |
| June 30, 2019 | -17.50M |
| March 31, 2019 | -16.58M |
| December 31, 2018 | -16.60M |
| September 30, 2018 | -12.80M |
| June 30, 2018 | -17.24M |
| March 31, 2018 | -19.97M |
| December 31, 2017 | -9.649M |
| September 30, 2017 | -17.57M |
| June 30, 2017 | -4.904M |
| March 31, 2017 | -17.54M |
| December 31, 2016 | -13.67M |
| September 30, 2016 | -14.54M |
| June 30, 2016 | -17.72M |
| March 31, 2016 | -11.55M |
| December 31, 2015 | -16.04M |
| September 30, 2015 | -0.6428M |
| June 30, 2015 | -17.96M |
| March 31, 2015 | -17.84M |
| December 31, 2014 | -6.491M |
| September 30, 2014 | -6.740M |
| June 30, 2014 | -8.004M |
| March 31, 2014 | 9.155M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Insmed, Inc. | -88.83M |
| Pfizer Inc. | 835.00M |
| Gossamer Bio, Inc. | -41.39M |
| Legend Biotech Corp. | -20.87M |
| Moderna, Inc. | -526.00M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -1.664M |
| Cash from Financing (Quarterly) | 3.079M |
| Free Cash Flow | -24.13M |
| Free Cash Flow Per Share (Quarterly) | -0.0301 |
| Free Cash Flow to Equity (Quarterly) | -5.668M |
| Free Cash Flow to Firm (Quarterly) | -5.934M |
| Free Cash Flow Yield | -2.94% |